Skip Navigation
Print This Page
Share this page: More

Richard Roden

Journal Citations

Bazzaro, M.; Lee, M.K.; Zoso, A.; Stirling, W.L.; Santillan, A.; Shih Ie, M.; Roden, R.B. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006 Apr 1;66(7):3754-3763.
Roden, R.; Wu, T.C. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006 Oct;6(10):753-763.
Berg, M.; Gambhira, R.; Siracusa, M.; Hoiczyk, E.; Roden, R.; Ketner, G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine. 2007 Apr 30;25(17):3501-3510.
Lin, Y.Y.; Alphs, H.; Hung, C.F.; Roden, R.B.; Wu, T.C. Vaccines against human papillomavirus. Front Biosci. 2007;12:246-264.
Peng, S.; Trimble, C.; Wu, L.; Pardoll, D.; Roden, R.; Hung, C.F.; Wu, T.C. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007 Apr 15;13(8):2479-2487.
Roden, R.B.; Monie, A.; Wu, T.C. Opportunities to improve the prevention and treatment of cervical cancer. Current molecular medicine. 2007 Aug;7(5):490-503.
Tesfaye, A.; Di Cello, F.; Hillion, J.; Ronnett, B.M.; Elbahloul, O.; Ashfaq, R.; Dhara, S.; Prochownik, E.; Tworkoski, K.; Reeves, R.; Roden, R.; Ellenson, L.H.; Huso, D.L.; Resar, L.M. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res. 2007 May 1;67(9):3998-4004.
Alphs, H.H.; Gambhira, R.; Karanam, B.; Roberts, J.N.; Jagu, S.; Schiller, J.T.; Zeng, W.; Jackson, D.C.; Roden, R.B. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5855.
Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M.K.; Wang, M.C.; Chan, K.C.; Bristow, R.E.; Mazitschek, R.; Bradner, J.; Roden, R.B. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res. 2008 Nov 15;14(22):7340-7347.
Day, P.M.; Gambhira, R.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol. 2008 May;82(9):4638-4646.
Huh, W.K.; Roden, R.B. The future of vaccines for cervical cancer. Gynecol Oncol. 2008 May;109(2 Suppl):S48-56.
Hung, C.F.; Wu, T.C.; Monie, A.; Roden, R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008 Apr;222:43-69.
Kim, D.; Gambhira, R.; Karanam, B.; Monie, A.; Hung, C.F.; Roden, R.; Wu, T.C. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008 Jan 17;26(3):351-360.
Kurman, R.J.; Visvanathan, K.; Roden, R.; Wu, T.C.; Shih Ie, M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008 Apr;198(4):351-356.
Roden, R.B.; Gravitt, P.; Wu, T.C. Towards global prevention of human papillomavirus-induced cancer. Eur J Immunol. 2008 Feb;38(2):323-326.
Conway, M.J.; Alam, S.; Ryndock, E.J.; Cruz, L.; Christensen, N.D.; Roden, R.B.; Meyers, C. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol. 2009 Oct;83(20):10515-10526.
Gambhira, R.; Jagu, S.; Karanam, B.; Day, P.M.; Roden, R. Role of L2 cysteines in papillomavirus infection and neutralization. Virol J. 2009;6:176.
Jagu, S.; Karanam, B.; Gambhira, R.; Chivukula, S.V.; Chaganti, R.J.; Lowy, D.R.; Schiller, J.T.; Roden, R.B. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009 Jun 3;101(11):782-792.
Karanam, B.; Gambhira, R.; Peng, S.; Jagu, S.; Kim, D.J.; Ketner, G.W.; Stern, P.L.; Adams, R.J.; Roden, R.B. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine. 2009 Feb 11;27(7):1040-1049.
Karanam, B.; Jagu, S.; Huh, W.K.; Roden, R.B. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009 May-Jun;87(4):287-299.
Li, J.; Sherman-Baust, C.A.; Tsai-Turton, M.; Bristow, R.E.; Roden, R.B.; Morin, P.J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009;9:244.
Lin, Z.; Bazzaro, M.; Wang, M.C.; Chan, K.C.; Peng, S.; Roden, R.B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res. 2009 Jan 15;15(2):570-577.
Lin, Z.; Yemelyanova, A.V.; Gambhira, R.; Jagu, S.; Meyers, C.; Kirnbauer, R.; Ronnett, B.M.; Gravitt, P.E.; Roden, R.B. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2009 Jan;174(1):136-143.
Schellenbacher, C.; Roden, R.; Kirnbauer, R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol. 2009 Oct;83(19):10085-10095.
Tsai-Turton, M.; Santillan, A.; Lu, D.; Bristow, R.E.; Chan, K.C.; Shih Ie, M.; Roden, R.B. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009 Jul;114(1):12-17.
Campo, M.S.; Roden, R.B. Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol. 2010 Feb;84(3):1214-1220.
Daayana, S.; Elkord, E.; Winters, U.; Pawlita, M.; Roden, R.; Stern, P.L.; Kitchener, H.C. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010 Mar 30;102(7):1129-1136.
Day, P.M.; Kines, R.C.; Thompson, C.D.; Jagu, S.; Roden, R.B.; Lowy, D.R.; Schiller, J.T. In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection. Cell Host Microbe. 2010 Sep 16;8(3):260-270.
Jagu, S.; Kwak, K.; Garcea, R.L.; Roden, R.B. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine. 2010 Jun 17;28(28):4478-4486.
Jones, S.; Wang, T.L.; Shih Ie, M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A., Jr.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E.; Papadopoulos, N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010 Oct 8;330(6001):228-231
Karanam, B.; Peng, S.; Li, T.; Buck, C.; Day, P.M.; Roden, R.B. Papillomavirus infection requires gamma secretase. J Virol. 2010 Oct;84(20):10661-10670.
Kwak, K.; Yemelyanova, A.; Roden, R.B. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2010 Dec 23.
Ma, B.; Roden, R.; Wu, T.C. Current status of human papillomavirus vaccines. J Formos Med Assoc. 2010 Jul;109(7):481-483.
Peng, S.; Monie, A.; Kang, T.H.; Hung, C.F.; Roden, R.; Wu, T.C. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther. 2010 Dec;17(12):1453-1464.


Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.